Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017" report to their offering.

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors.

This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs.

This report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Companies Mentioned

- AbbVie

- Aclaris Therapeutics International Limited (ATIL)

- Advinus Therapeutics

- Amgen

- Aptose Biosciences

- Arrien Pharmaceuticals

- Asana BioSciences

- Astellas Pharma

- Astrazeneca

- Bristol-Myers Squibb

- CleveXel Pharma

- Cloud pharmaceuticals

- Concert Pharmaceuticals

- CTI BioPharma

- Eli Lilly and Company

- Galapagos NV

- Gilead Sciences

- Hoffmann-La Roche

- Incyte Corporation

- Japan Tobacco Company

- Nimbus Therapeutics

- Pfizer

- Portola Pharmaceuticals

- Sareum Limited

- Theravance Biopharma

- Tragara Pharmaceuticals

- Vectura Group plc

For more information about this report visit http://www.researchandmarkets.com/research/n9scb5/janus_kinase

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Oncology Drugs , Enzymes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Oncology Drugs , Enzymes